Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2004-08-30
2009-08-25
Parkin, Jeffrey S (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100
Reexamination Certificate
active
07579008
ABSTRACT:
The invention provides a method of inducing an immune response against rotavirus infection from one rotavirus serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a different serotype. There is in particular provided a method of inducing an immune response against rotavirus infection from a non-G1 serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a G1 serotype.
REFERENCES:
patent: 5474773 (1995-12-01), Ward
patent: 5932223 (1999-08-01), Burke et al.
patent: 6130082 (2000-10-01), Majarian et al.
patent: 2002/0058043 (2002-05-01), Hoshino et al.
patent: WO 01/12797 (2001-02-01), None
Pérez-Schael et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. The New England Journal of Medicine, Oct. 23, 1997, Vo. 337, No. 17, pp. 1181-1187.
Bernstein et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998, vol. 16, No. 4, pp. 381-387.
Ruiz-Palacios et al. Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis. The New England Journal of Medicine 2006, vol. 354, No. 1, pp. 11-22.
Glass et al. The Promise of New Rotavirus Vaccines. The New England Journal of Medicine 2006, vol. 354, pp. 75-77.
Barnes, et al., “Early Phase II Trial of Human Rotavirus Vaccine Candidate RV3,”Vaccine, 2002, 20:2950-2956.
Perez-Schael, et al., “Protective Efficacy of an Oral Human Rotavirus (HRV) Vaccine in Latin American Infants,” 42ndInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sep. 27-30, 2002, San Diego, USA.
Yuan, et al., “Homotypic and Heterotypic Serum Isotype-Specific Antibody Responses to Rotavirus Nonstructural Protein 4 and Viral Protein (VP) 4, VP6, and VP7 in Infants Who Received Selected Live Oral Rotavirus Vaccines,”The Journal of Infectious Diseases, 2004, 189:1833-1845.
Vesikari, et al., “Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants,”The Pediatric Infectious Disease Journal, 2004, 23(10):937-943.
DeVos, et al., “A Rotavirus Vaccine for Prophylaxis of Infants Against Rotavirus Gastroenteritis,”The Pediatric Infectious Disease Journal, 2004, 23(10):S179-S182.
Berstein, et al., “Protection from Rotavirus Reinfection: 2-Year Prospective Study,” tThe Journal of Infectious Diseases, 1991, 164:277-283.
Valázquez, et al., “Rotavirus Infection in Infants as Protection Against Subsequent Infections,”The New England Journal of Medicine, 1996, 335(14):1022-1028.
PCT International Search Report (International Application No. PCT/EP2004/009725).
Colau Brigitte Desiree Alberte
De Vos Beatrice Arsene Virginie
GlaxoSmithKline Biologicals s.a.
GlaxoSmithKline Corporate Intellectual Property
Humphrey Louise
Parkin Jeffrey S
Warren Gwynedd
LandOfFree
Immunization with an attenuated human rotavirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunization with an attenuated human rotavirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunization with an attenuated human rotavirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4124148